NCT06301009

Brief Summary

The AI-CAC model is an artificial intelligence system capable of assessing the presence of subclinical atherosclerosis on a simple chest radiograph. The present study will provide prospective validation of its diagnostic performance in a primary prevention population with a clinical indication for coronary artery calcium (CAC) testing.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
500

participants targeted

Target at P75+ for not_applicable cardiovascular-diseases

Timeline
Completed

Started Apr 2024

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 26, 2024

Completed
11 days until next milestone

First Posted

Study publicly available on registry

March 8, 2024

Completed
24 days until next milestone

Study Start

First participant enrolled

April 1, 2024

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2025

Completed
Last Updated

March 8, 2024

Status Verified

March 1, 2024

Enrollment Period

1.5 years

First QC Date

February 26, 2024

Last Update Submit

March 3, 2024

Conditions

Keywords

coronary artery calciumchest x-rayatherosclerotic cardiovascular diseaseprimary preventionrisk predictionartificial intelligence

Outcome Measures

Primary Outcomes (1)

  • Diagnostic accuracy of the AI-CAC score to identify the presence of subclinical atherosclerosis on chest x-ray

    Diagnostic accuracy of the AI-CAC score to identify the presence of subclinical atherosclerosis (i.e. AI-CAC \>0) on chest x-ray as compared to CAC measured on a non-contrast ECG-gated CT scan (i.e. CAC \>0). The area under the curve (AUC) method will be used to evaluate the primary outcome.

    Through study completion (anticipated average follow-up of 1 year).

Secondary Outcomes (2)

  • Percentage of individuals with a therapeutic management change by the attending physician based on the CAC score, with concordant AI-CAC.

    Through study completion (anticipated average follow-up of 1 year).

  • Comparison of ASCVD events occurring in patients without (AI-CAC=0) vs. with subclinical atherosclerosis (AI-CAC >0) based on the AI-CAC score, as assessed by Kaplan Meier estimates of ASCVD events occurring until study completion.

    Through study completion (anticipated average follow-up of 1 year).

Study Arms (1)

AI-CAC arm

EXPERIMENTAL

All patients included in the study and undergoing AI-CAC calculation on a chest x-ray

Diagnostic Test: AI-CAC score

Interventions

AI-CAC scoreDIAGNOSTIC_TEST

Deep-learning based prediction of the coronary artery calcium score with a plain chest x-ray

AI-CAC arm

Eligibility Criteria

Age40 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Consent to participate in the study
  • Age between 40 and 75 years
  • Clinical indication from the treating physician to undergo chest CT for CAC score evaluation

You may not qualify if:

  • Prior cardiovascular events (myocardial infarction, coronary revascularization, transient ischemic attack, stroke, symptomatic peripheral vascular disease, arterial revascularization of peripheral districts)
  • Cancer or other chronic diseases with an estimated prognosis of less than five years
  • Technical contraindications to the execution of chest CT with electrocardiographic gating (highly penetrant atrial fibrillation, frequent ventricular extrasystoles)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Cardiovascular DiseasesAtherosclerosis

Condition Hierarchy (Ancestors)

ArteriosclerosisArterial Occlusive DiseasesVascular Diseases

Central Study Contacts

Fabrizio D'Ascenzo, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
PREVENTION
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD, PhD

Study Record Dates

First Submitted

February 26, 2024

First Posted

March 8, 2024

Study Start

April 1, 2024

Primary Completion

October 1, 2025

Study Completion

October 1, 2025

Last Updated

March 8, 2024

Record last verified: 2024-03

Data Sharing

IPD Sharing
Will share

Publication in peer-reviewed cardiovascular journal